- •Chemotherapy and surgical resection improve survival in stage III PDAC.
- •Patients diagnosed at high-volume centers are more likely to receive combined chemotherapy and surgical resection.
- •Diagnosis at a high-volume center, later year of diagnosis, and younger age are associated with receipt of combined therapy.
Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at a locally advanced stage with vascular involvement which was previously viewed as a contraindication to resection. However, high-volume centers are increasingly capable of resecting complex tumors. We aimed to explore patterns of treatment that are uncharacterized on a population level.
A statewide registry was queried from 2003 to 2018 for stage III PDAC. Stepwise logistic regression and Kaplan-Meier were used for statistical analysis.
We identified 424 eligible patients. 348 (82%) received chemotherapy, 17 (4.0%) received resection, and 59 (13.9%) received both; median survival was 10.7, 8.7, and 22.7 months, respectively (P < 0.001). High-volume centers (≥20 cases per year; OR 5.40 [95% CI: 2.76, 10.58], P < 0.001) and later year of diagnosis (OR 1.12/year [95% CI: 1.04, 1.20], P = 0.004) were associated with higher odds of receiving combined therapy.
PDAC patients with vascular involvement who receive both systemic chemotherapy and surgical resection have improved overall survival. High-volume centers are independently associated with higher odds of receiving combined systemic therapy and surgical resection.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The American Journal of Surgery
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Outcomes of neoadjuvant chemotherapy versus chemoradiation in localized pancreatic cancer: a case-control matched analysis.Ann Surg Oncol. Jul 2021; 28: 3779-3788https://doi.org/10.1245/s10434-020-09391-9
- The impact of neoadjuvant treatment on survival in patients undergoing pancreatoduodenectomy with concomitant portomesenteric venous resection: an international multicenter analysis.Ann Surg. Nov 1. 2021; 274: 721-728https://doi.org/10.1097/sla.0000000000005132
- Treatment patterns and outcomes in resected pancreatic cancers: frequent deviations from standard of care.HPB. 2020; 22: S91-S92https://doi.org/10.1016/j.hpb.2020.04.574
- Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma.JAMA Surgical resection. 2019; 154: 932-942https://doi.org/10.1001/jamasurg.2019.2277
- Preoperative chemoradiotherapy versus immediate surgical resection for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial.J Clin Oncol. Jun 1 2020; 38: 1763-1773https://doi.org/10.1200/jco.19.02274
- Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology.J Natl Compr Cancer Netw. Apr 1 2021; 19: 439-457https://doi.org/10.6004/jnccn.2021.0017
- Going the extra mile: improved survival for pancreatic cancer patients traveling to high-volume centers.Ann Surg. Aug 2017; 266: 333-338https://doi.org/10.1097/sla.0000000000001924
- The effect of center esophagectomy volume on outcomes in clinical stage I-III esophageal cancer.Ann Surg. Aug 30 2022; https://doi.org/10.1097/sla.0000000000005681
- Long-term survival is superior after resection for cancer in high-volume centers.Ann Surg. Oct 2005; 242 (; discussion 544-7): 540-544https://doi.org/10.1097/01.sla.0000184190.20289.4b
- Venous resection in pancreatic ductal adenocarcinoma: impact of surgical experience on early postoperative courses.Anticancer Res. Aug 2017; 37: 4205-4213https://doi.org/10.21873/anticanres.11811
- Effect of centralization on long-term survival after resection of pancreatic ductal adenocarcinoma.Br J Surg. Oct 2017; 104: 1532-1538https://doi.org/10.1002/bjs.10560
- Pancreatic resection at high volume centers improves survival.HPB. 2017; 19: S171https://doi.org/10.1016/j.hpb.2017.02.384
- Laparoscopic pancreatectomy for cancer in high volume centers is associated with an increased use and fewer delays of adjuvant chemotherapy.HPB. 2021; 23: 625-632https://doi.org/10.1016/j.hpb.2020.09.003
- Treatment differences at high volume centers and low volume centers in non-metastatic and metastatic adrenocortical carcinoma.Am J Surg Resect. 2022/03/01/2022; 223: 582-586https://doi.org/10.1016/j.amjsurg.2022.01.004
- Centralization of pancreatic cancer treatment within an integrated healthcare system improves overall survival.Am J Surg. Jun 2022; 223: 1035-1039https://doi.org/10.1016/j.amjsurg.2021.09.036
- Pancreaticoduodenectomy with vascular resection: margin status and survival duration.J Gastrointest Surg. Dec 2004; 8 (; discussion 949-50): 935-949https://doi.org/10.1016/j.gassur.2004.09.046
- A real-world, population-based study of patterns of referral, treatment, and outcomes for advanced pancreatic cancer.Cancer Med. Dec 2018; 7: 6385-6392https://doi.org/10.1002/cam4.1841
- Variations in referral patterns to high-volume centers for pancreatic cancer.J Am Coll Surg. Dec 2009; 209: 720-726https://doi.org/10.1016/j.jamcollsurg.2009.09.011
- Vascular reconstruction plays an important role in the treatment of pancreatic adenocarcinoma.J Vasc Surg. Feb 2015; 61: 475-480https://doi.org/10.1016/j.jvs.2014.09.003
- Portal vein resection in borderline resectable pancreatic cancer: a United Kingdom multicenter study.J Am Coll Surg. Mar 2014; 218: 401-411https://doi.org/10.1016/j.jamcollsurg.2013.11.017
- Portal vein resection in advanced pancreatic adenocarcinoma: is it worth the risk?.Wien Klin Wochenschr. Aug 2016; 128: 566-572https://doi.org/10.1007/s00508-016-1024-7
- Socioeconomic and geographic disparities in the referral and treatment of pancreatic cancer at high-volume centers.JAMA surgery. 2022; (Advance online publication)e226709
Published online: February 21, 2023
Accepted: February 17, 2023
Received in revised form: January 22, 2023
Received: November 15, 2022
Publication stageIn Press Journal Pre-Proof
© 2023 Elsevier Inc. All rights reserved.